124 related articles for article (PubMed ID: 37087327)
1. Dose and secondary cancer-risk estimation of patients undergoing high dose rate intracavitary gynaecological brachytherapy.
Doudoo CO; Gyekye PK; Emi-Reynolds G; Adu S; Kpeglo DO; Nii Adu Tagoe S; Agyiri K
J Med Imaging Radiat Sci; 2023 Jun; 54(2):335-342. PubMed ID: 37087327
[TBL] [Abstract][Full Text] [Related]
2. Secondary cancer-incidence risk estimates for external radiotherapy and high-dose-rate brachytherapy in cervical cancer: phantom study.
Lee B; Ahn SH; Kim H; Son J; Sung J; Han Y; Huh SJ; Kim JS; Kim DW; Yoon M
J Appl Clin Med Phys; 2016 Sep; 17(5):124-132. PubMed ID: 27685104
[TBL] [Abstract][Full Text] [Related]
3. Effect of bladder distention on bladder base dose in gynaecological intracavitary high dose rate brachytherapy.
Adli M; Garipagaoglu M; Kocak Z
Br J Radiol; 2009 Mar; 82(975):243-8. PubMed ID: 19064593
[TBL] [Abstract][Full Text] [Related]
4. Evaluating adjacent organ radiation doses from postoperative intracavitary vaginal vault brachytherapy for endometrial cancer.
Caon J; Holloway C; Dubash R; Yuen C; Aquino-Parsons C
Brachytherapy; 2014; 13(1):94-9. PubMed ID: 24269147
[TBL] [Abstract][Full Text] [Related]
5. [Historical overview and the current practice of intracavitary treatment of cervical and endometrial cancer in the Oncoradiology Center of Budapest].
Sinkó D; Nemeskéri C; Pallinger Á; Weisz C; Naszály A; Landherr L
Magy Onkol; 2015 Jun; 59(2):140-7. PubMed ID: 26035162
[TBL] [Abstract][Full Text] [Related]
6. Comparing organ-at-risk doses for high-dose-rate vaginal brachytherapy between three different planning workflows.
Gruhl JD; Zheng D; Longo JL; Enke C; Wahl AO
Brachytherapy; 2017; 16(2):373-377. PubMed ID: 28039010
[TBL] [Abstract][Full Text] [Related]
7. Second primary malignancies after high-dose-rate
Janulionis E; Samerdokiene V; Valuckas KP; Atkocius V; Rivard MJ
Brachytherapy; 2018; 17(5):768-774. PubMed ID: 29895451
[TBL] [Abstract][Full Text] [Related]
8. Image-guided high-dose-rate intracavitary brachytherapy in the treatment of medically inoperable early-stage endometrioid type endometrial adenocarcinoma.
Jordan SE; Micaily I; Hernandez E; Ferriss JS; Miyamoto CT; Li S; Micaily B
Brachytherapy; 2017; 16(6):1144-1151. PubMed ID: 28958736
[TBL] [Abstract][Full Text] [Related]
9. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
[TBL] [Abstract][Full Text] [Related]
10. Perioperative morbidity and mortality of high-dose-rate gynecologic brachytherapy.
Petereit DG; Sarkaria JN; Chappell RJ
Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):1025-31. PubMed ID: 9869225
[TBL] [Abstract][Full Text] [Related]
11. An analysis of simulation for adjuvant intracavitary high-dose-rate brachytherapy in early-stage endometrial cancer.
Barney BM; MacDonald OK; Lee CM; Rankin J; Gaffney DK
Brachytherapy; 2007; 6(3):201-6. PubMed ID: 17681241
[TBL] [Abstract][Full Text] [Related]
12. A new method of anatomically conformal vaginal cuff HDR brachytherapy.
Miller DA; Richardson S; Grigsby PW
Gynecol Oncol; 2010 Mar; 116(3):413-8. PubMed ID: 19892389
[TBL] [Abstract][Full Text] [Related]
13. High-dose-rate intracavitary brachytherapy for gynecologic malignancies.
Stitt JA
Oncology (Williston Park); 1992 Jan; 6(1):59-70, 79; discussion 80-2. PubMed ID: 1531604
[TBL] [Abstract][Full Text] [Related]
14. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium.
Nag S; Erickson B; Parikh S; Gupta N; Varia M; Glasgow G
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):779-90. PubMed ID: 11020575
[TBL] [Abstract][Full Text] [Related]
15. Triple-tandem high-dose-rate brachytherapy for early-stage medically inoperable endometrial cancer: Initial report on acute toxicity and dosimetric comparison to stereotactic body radiation therapy.
Kauffmann G; Wu T; Al-Hallaq H; Hasan Y
Brachytherapy; 2017; 16(1):141-146. PubMed ID: 27866953
[TBL] [Abstract][Full Text] [Related]
16. Medically inoperable endometrial cancer in patients with a high body mass index (BMI): Patterns of failure after 3-D image-based high dose rate (HDR) brachytherapy.
Acharya S; Esthappan J; Badiyan S; DeWees TA; Tanderup K; Schwarz JK; Grigsby PW
Radiother Oncol; 2016 Jan; 118(1):167-72. PubMed ID: 26743834
[TBL] [Abstract][Full Text] [Related]
17. Postoperative intravaginal brachytherapy for endometrial cancer; dosimetric analysis of vaginal colpostats and cylinder applicators.
Kim RY; Pareek P; Duan J; Murshed H; Brezovich I
Brachytherapy; 2002; 1(3):138-44. PubMed ID: 15090276
[TBL] [Abstract][Full Text] [Related]
18. Low-Dose Adjuvant Cylinder Brachytherapy for Endometrioid Endometrial Cancer.
Alban GM; Buscariollo DL; Cheng T; Pretz J; Krechmer B; Buzurovic I; Singer L; King M; Lee L
Pract Radiat Oncol; 2020; 10(2):95-103. PubMed ID: 31783169
[TBL] [Abstract][Full Text] [Related]
19. Body mass index, dose to organs at risk during vaginal brachytherapy, and the role of three-dimensional CT-based treatment planning.
Boyle JM; Craciunescu O; Steffey B; Cai J; Chino J
Brachytherapy; 2014; 13(4):332-6. PubMed ID: 24439964
[TBL] [Abstract][Full Text] [Related]
20. Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification.
Vargo JA; Kim H; Houser CJ; Berhane H; Sukumvanich P; Olawaiye AB; Kelley JL; Edwards RP; Comerci JT; Huang M; Courtney-Brooks M; Beriwal S
Radiother Oncol; 2014 Oct; 113(1):126-31. PubMed ID: 25241996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
